WHAT IS CLAIMED IS:

1. A heat-stable, ophthalmically-acceptable aqueous solution comprising an amine buffer and a muscarinic acetylcholine receptor antagonist selected from atropine or pirenzepine or a pharmaceutically acceptable salt thereof, wherein the amine buffer is bis(2-Hydroxyethyl)iminotris(hydroxymethyl)methane (Bis-Tris).

2. The heat-stable, ophthalmically-acceptable aqueous solution of claim 1, having a pH in the range of 5.0 to 7.5.

3. The heat-stable, ophthalmically-acceptable aqueous solution of claim 1, having a pH of 5.8 to 7.4.

4. The heat-stable, ophthalmically-acceptable aqueous solution of any one of claims 1 to 3, comprising 0.001 wt.% to 5.0 wt % muscarinic acetylcholine receptor antagonist.

5. The heat-stable, ophthalmically-acceptable aqueous solution of any one of claims 1 to 4 comprising

0.001M-0.5M Bis-tris; and

0.001 wt.% to 5.0 wt % muscarinic acetylcholine receptor antagonist.

6. The heat-stable, ophthalmically-acceptable aqueous solution of any one of claims 1 to 3 wherein less than 10% (by weight) of the muscarinic acetylcholine receptor antagonist degrades during autoclave at 121°C (at 1 atm (101kPa)) for 30 minutes at 17 psi.

7. The heat-stable, ophthalmically-acceptable aqueous solution of any preceding claim, wherein the muscarinic acetylcholine receptor antagonist is atropine.

8. The heat-stable, ophthalmically-acceptable aqueous solution of any preceding claim, wherein the composition is preservative-free.

9. The heat-stable, ophthalmically-acceptable aqueous solution of any preceding claim, wherein the composition further comprises EDTA.

10. The heat-stable, ophthalmically-acceptable aqueous solution of any preceding claim, wherein the composition further comprises an agent capable of increasing intermolecular hydrogen bonding which further stabilizes the muscarinic acetylcholine receptor antagonist after autoclave resulting in fewer muscarinic acetylcholine receptor antagonist degradation products.

11. The heat-stable, ophthalmically-acceptable aqueous solution of any preceding claim, comprising an aqueous component that consists of or comprises deuterated water.

12. The heat-stable, ophthalmically-acceptable aqueous solution of any preceding claim, wherein the composition further comprises trehalose.

13. A container containing the heat-stable, ophthalmically-acceptable aqueous solution of any preceding claim.

14. The container of claim 13, wherein the container is a multi-use or single-use eye drop dispensing bottle or vial.

15. The container of claim 13 or claim 14, wherein the container further contains a contact lens.

16. The container of any one of claims 13-15, wherein the container is sterilized by autoclaving.

17. A method of manufacturing the container of any one of claims 13-16 comprising:

(a) placing the liquid ophthalmically-acceptable aqueous solution of any one of claims 1 to 12 in a container,

(b) sealing the container, and

(c) heat sterilizing the sealed container.

18. A container containing the ophthalmically-acceptable aqueous solution of any one of claims 1-12, wherein the solution has been sterilized by filtration.

19. The container of claim 18, wherein the container is a multi-use or single-use eye drop dispensing bottle or vial.